We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Commercial Kits Evaluated for Rapid Diagnosis of Tuberculosis

By LabMedica International staff writers
Posted on 11 Oct 2015
Print article
The T-SPOT.TB interferon-gamma release assay kit, a blood test for the detection of active and latent tuberculosis infection
The T-SPOT.TB interferon-gamma release assay kit, a blood test for the detection of active and latent tuberculosis infection (Photo courtesy of OXFORD IMMUNOTEC - A Perkin Elmer Company)
The tuberculosis (TB) interferon-gamma release assay (IGRA) detects the release of interferon-gamma (IFN-γ) in fresh heparinized whole blood samples from test subjects.

In IGRA assays, the blood samples are incubated with mixtures of the two specific Mycobacterium antigens present in Mycobacterium tuberculosis: early secretory antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10).

Scientists at the Chinese Center for Disease Control and Prevention (Beijing, China) enrolled a total of 1,026 participants at three hospitals, including 597 tuberculosis (TB) patients diagnosed clinically (517 patients with pulmonary TB and 80 patients with extrapulmonary TB) and 429 negative controls (244 patients with pulmonary disease but not TB, or with non-tuberculosis mycobacterial lung diseases), and 185 healthy people. Detection performance indicators including sensitivity, specificity, and the Youden index (YI) were used to evaluate performance of commercial IGRA kits.

Blood specimens and sputum samples were tested and analyzed with bacteriological assays (including sputum smear and bacterial culture) and the three commercial cellular immune detection kits: TB.IGRA (Beijing Wantai Biopharm Co., Ltd.; Beijing, China), QB.SPOT (Kinghawk Pharmaceutical Co., Ltd.; Beijing, China), and T-SPOT.TB (Oxford Immunotec; Oxford, UK) simultaneously. Sputum samples from the pulmonary TB patients were subjected to smear acid-fast staining, followed by Mycobacterium culture on Löwenstein–Jensen medium.

Among 597 clinically diagnosed TB patients, the sensitivity of T-SPOT.TB, QB-SPOT, and TB-IGRA was 78.2%, 78.9%, and 74.9%, respectively, with no significant difference in sensitivity among the three kits. For the 80 extrapulmonary TB cases, the sensitivity of T-SPOT.TB, QB-SPOT, and TB-IGRA was 66.3%, 70.0%, and 68.8%, respectively, with no significant difference in sensitivity among the three kits. For the 517 PTB patients, the sensitivity of T-SPOT.TB, QB-SPOT, and TB-IGRA was 81.1%, 80.3%, and 75.8%, respectively. This was compared to 24.7% (125/507) for smear staining and 45.0% (219/487) for bacterial culture. There was a significant difference in sensitivity between the bacterial methods and the three kits .There was a significant difference in sensitivity of T-SPOT.TB and QB-SPOT between PTB and extrapulmonary TB patients, but not for TB-IGRA.

The authors concluded that the data obtained in the current study suggest that the three commercial kits have comparable detection performance in PTB when the bacteriological method is used as the “gold standard.” These kits will also be a very useful aid in the clinical detection and diagnosis of M. tuberculosis infection, especially in patients with smear-negative and culture-negative and extrapulmonary TB. The kits will be beneficial for TB control in China and elsewhere. The study was published online on September 7, 2015 in the International Journal of Infectious Diseases.

Related Links:
Chinese Center for Disease Control and Prevention
Beijing Wantai Biopharm Co., Ltd. 
Oxford Immunotec 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.